Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong speaks to Proactive's Andrew Scott following the news of a major milestone with US collaborator City of Hope® securing Investigational New Drug (IND) approval for an upcoming phase one trial of its oncolytic virotherapy candidate. The clinical-stage immuno-oncology company has partnered with the City of Hope, a world-renowned independent cancer research and treatment centre near Los Angeles, to conduct the study.
Imugene's Leslie Chong welcomes IND approval for CHECKvacc trial
